Literature DB >> 20020962

Genotoxicity of DNA Intercalating Anticancer Drugs: Pyrimido[4(I),5(I):4,5] thieno(2,3-b)quinolines on Somatic and Germinal Cells.

M S Shahabuddin1, M Gopal.   

Abstract

ABSTRACT The genotoxic effect of the anticancer drugs Oxo-PTQ, Morpholino-PTQ, and Chloro-PTQ were studied in mice bone marrow by means of chromosome aberrations and micronucleus assay. These drugs, at dose levels of 21.42, 28.57, and 35.71 mg/kg b.w., respectively, were given to mice in a single application via the intraperitoneal route. Marrow was collected at 24, 48, and 72 h after the application. The chromosome aberrations and micronucleus assay were done according to standard procedures. These compounds gave rise to an increase in the number of micronuclei in a dose-dependent manner. The number of micronucleated polychromatic erythrocytes showed a maximum at 24 h, and there was partial recovery at 72 h. Chromosome aberrations increased significantly as compared to normal controls when treated with Oxo-PTQ followed by Morpholino-PTQ at 21.42 mg/kg b.w. (48 h). Statistically significant sperm abnormalities also revealed the genotoxic potency of these drugs. Our results suggest that the Pyrimido[4(I),5(I):4,5]thieno(2,3-b)quinoline drugs owe at least some of their cytotoxicity to their genotoxic effects, which seem to be mediated through interaction with topoisomerase II.

Entities:  

Year:  2007        PMID: 20020962     DOI: 10.1080/15376510600899605

Source DB:  PubMed          Journal:  Toxicol Mech Methods        ISSN: 1537-6516            Impact factor:   2.987


  1 in total

1.  Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity.

Authors:  Dmitri Rozanov; Anton Cheltsov; Aaron Nilsen; Christopher Boniface; Isaac Forquer; James Korkola; Joe Gray; Jeffrey Tyner; Cristina E Tognon; Gordon B Mills; Paul Spellman
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.